Global API market revenues to reach $143 billion in 2016
![](/46/pdcnewsitem/04/16/70/persistence%20market%20research.png)
According to a New Market Report Published by Persistence Market Research, the Global API market is estimated to reach $186 billion by 2020, with North America accounting for 35% revenue shares..
The global API market was valued at US$ 135 billion in 2015 and is expected to grow at a year over year rate of 6.4% to reach $ 143 billion in 2016. North America will remain the most lucrative market for APIs, representing a revenue share of 35% in 2016.
Increase in global incidences of lifestyle related diseases and development of high potency APIs will continue to positively influence the global API market in 2016. Demand for active pharmaceutical ingredients is also growing due to increase in the geriatric population globally. These factors are expected to support the growth of the market in 2016 and beyond.
On the basis of manufacturing process type, the global pharmaceutical ingredient market is segmented into API manufacturing type and contract API. The API manufacturing includes captive or in-house API. In terms of revenue, captive manufacturing type accounted for higher share of the market than in-house API in 2015. However, owing to concerns regarding its limitation on manufacturing niche APIs and high production cost, manufacturers are looking for alternatives, fuelling the growth of the in-house API segment.
On the basis of API types, the market is segmented into synthetic chemical APIs and biological APIs. While synthetic chemical API segment accounted for a higher revenue share of the market in 2015, biological API is expected register a witness a higher year-over-year growth in 2016. Furthermore, major pharmaceutical companies are preferring biological API segment.
On the basis of drug type, branded API segment accounted for higher revenue share than over-the-counter (OTC) drugs, and generic prescription drugs in 2015. However, owing to their low cost manufacturing process, generic prescription drug segment is expected to expand at a higher year-over-year growth in 2016.
On the basis of therapeutic areas, the global API market is segmented into disorders such as metabolic, cardiovascular, oncology, neurological, musculoskeletal, non-steroidal anti-inflammatory drugs (NSAIDs), and other therapeutic uses. Cardiovascular Drugs is the largest segment in terms of revenues, accounting for a revenue share of 24% in 2015. On the other hand, the oncology segment is expected to witness the highest year-over-year growth in 2016 over 2015.
Asia Pacific is the second-largest market for APIs globally, with factors, such as availability of low cost production facilities making the region a key manufacturing hub globally. The region is home to over 60% of world's population, with a high percentage that can be categorised as geriatric.
Key players in the global API market include Teva Pharmaceutical Industries Ltd., and Zhejiang NHU Co., Ltd, Zhejiang Medicine Co.North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Sandoz (Novartis AG), Zhejiang Huahai Pharmaceutical Co.,Ltd, Ltd and Zhejiang Hisun Pharmaceutical Co., Ltd.
Long-term Outlook: The global active pharmaceutical ingredients market is expected to increase at a CAGR of 6.6% during the forecast period from 2015 to 2020 and reach US$185 Bn in revenues by 2020 end. North America will remain the largest market, with revenues increasing at a CAGR of 6.6% during the forecast period.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance